- Home
- ELLO vs INBX Comparison
ELLO vs INBX Comparison
Compare ELLO & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELLO
- INBX
- Stock Information
- Founded
- ELLO 1987
- INBX 2010
- Country
- ELLO Israel
- INBX United States
- Employees
- ELLO N/A
- INBX N/A
- Industry
- ELLO Electric Utilities: Central
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- ELLO Utilities
- INBX Health Care
- Exchange
- ELLO Nasdaq
- INBX Nasdaq
- Market Cap
- ELLO 208.2M
- INBX 178.5M
- IPO Year
- ELLO 1995
- INBX 2020
- Fundamental
- Price
- ELLO N/A
- INBX $16.33
- Analyst Decision
- ELLO
- INBX Hold
- Analyst Count
- ELLO 0
- INBX 1
- Target Price
- ELLO N/A
- INBX N/A
- AVG Volume (30 Days)
- ELLO 4.7K
- INBX 84.1K
- Earning Date
- ELLO 06-30-2025
- INBX 08-12-2025
- Dividend Yield
- ELLO N/A
- INBX N/A
- EPS Growth
- ELLO N/A
- INBX N/A
- EPS
- ELLO 0.43
- INBX 111.58
- Revenue
- ELLO $44,405,534.00
- INBX $200,000.00
- Revenue This Year
- ELLO N/A
- INBX N/A
- Revenue Next Year
- ELLO N/A
- INBX N/A
- P/E Ratio
- ELLO $45.19
- INBX $0.15
- Revenue Growth
- ELLO N/A
- INBX N/A
- 52 Week Low
- ELLO $11.30
- INBX $10.80
- 52 Week High
- ELLO $20.81
- INBX $17.79
- Technical
- Relative Strength Index (RSI)
- ELLO 61.85
- INBX 68.23
- Support Level
- ELLO $16.61
- INBX $13.97
- Resistance Level
- ELLO $18.54
- INBX $15.25
- Average True Range (ATR)
- ELLO 0.89
- INBX 0.75
- MACD
- ELLO 0.31
- INBX 0.06
- Stochastic Oscillator
- ELLO 77.96
- INBX 99.16
About ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is focused on the utility sector. It is an Israeli public company, which focuses its business in the energy and infrastructure sectors. The company's operating segment includes Photovoltaic power plants (PV Plants); Dorad Energy Ltd. (Dorad); Groen Gas Goor B.V. and a Pumped storage hydro power plant (Manara). It generates maximum revenue from the Dorad segment. Geographically, it derives a majority of its revenue from Spain.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.